SAB Biotherapeutics, Inc. (SABS) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
SABS EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SABS Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | -262.4% | -3244.9% | -2579.0% |
| 2023 | -67.3% | -1700.5% | -1884.5% |
| 2022 | 86.2% | -121.0% | -78.4% |
| 2021 | 97.3% | -22.0% | -28.2% |
Download Data
Export SABS earnings history in CSV or JSON format
Free sign-in required to download data
SAB Biotherapeutics, Inc. (SABS) Earnings Overview
As of May 8, 2026, SAB Biotherapeutics, Inc. (SABS) reported trailing twelve-month net income of $13M, reflecting +78.5% year-over-year growth. The company earned $0.22 per diluted share over the past four quarters.
Looking at the long-term picture, SABS's historical earnings data spans multiple years. The company achieved its highest annual net income of $20M in fiscal 2020.
SAB Biotherapeutics, Inc. maintains positive profitability with. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including IMVT (-$464M net income), ARGX ($1.95B net income, 31.1% margin), HALO ($317M net income, 22.7% margin), SABS has comparable earnings metrics. Compare SABS vs IMVT →
SABS Earnings vs Peers
Earnings metrics vs comparable public companies
SABS Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $13M | +138.9% | -$49M | $-0.79 | - | - |
| 2024 | -$34M | +19.2% | -$43M | $-3.68 | -2579.0% | -3244.9% |
| 2023 | -$42M | -125.1% | -$38M | $-7.64 | -1884.5% | -1700.5% |
| 2022 | -$19M | -9.3% | -$29M | $-4.31 | -78.4% | -121.0% |
| 2021 | -$17M | -185.2% | -$13M | $-6.30 | -28.2% | -22.0% |
| 2020 | $20M | +323.9% | $21M | $7.45 | 36.4% | 37.2% |
| 2019 | -$9M | - | -$9M | $-0.22 | -261.1% | -252.0% |
See SABS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SABS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SABS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSABS — Frequently Asked Questions
Quick answers to the most common questions about buying SABS stock.
Is SABS growing earnings?
SABS EPS is $0.22, with earnings growth accelerating to +78.5%. This exceeds the 5-year CAGR of N/A. TTM net income reached $13M.
What are SABS's profit margins?
SAB Biotherapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are SABS's earnings?
SABS earnings data spans 2019-2025. The accelerating earnings trend is +78.5% YoY. Historical data enables comparison across business cycles.